



1 **Anfrage zur Teilnahme an medizinischer Forschung:**

2

3

4 **Predicting individual fatigue levels based on brain connectivity – Pilot**  
5 **Study (QFMRI)**

6

7

8 Dear study participant

9

10 We are asking you here if you would be willing to participate in our research project.

11

12 Your participation is voluntary. All data collected in this research project is subject to strict data  
13 protection regulations.

14

15 The research project will be conducted by Prof. Dr. med. Klaas Enno Stephan and Dr. Sandra  
16 Iglesias, Translational Neuromodeling Unit (TNU) der Universität und ETH Zürich. If you are  
17 interested, we would be happy to provide you with information about the results of this research  
18 project.

19

20 We will explain the most important points to you and answer your questions. So that you can already  
21 get an idea, here is the most important information in advance. Further, more detailed information  
22 will follow.

23 **Why do we carry out this research project?**

- 24
- In this study we would like to test and optimise new cognitive tasks centred on the  
25 evaluation and experience of fatigue (a chronic state of exhaustion). Furthermore,  
26 we would like to understand how subjectively perceived fatigue levels are  
27 associated with the functional connectivity strength in the brain. To this end, we will  
28 perform fMRI measurements.

29 **What does participating in this research project mean for you?**

- 30
- Type of participation: Participation in the study includes filling in of questionnaires  
31 and one magnetic resonance imaging (MRI) session.
  - Participation overview: If you decide to participate in our study, you will be asked to  
32 complete an online pre-screening from home (approx. 30 minutes). If you are  
33 selected for the study, this is followed by online questionnaires that you can fill in  
34 from home (ca. 1 h 25 min: Informed consent and questionnaires) and one MRI  
35 appointment (approx. 3 h) at the University Hospital Zurich.
- 36

37 **What are the benefits and risks associated with participation in this study?**

38 **Benefits**

- 39
- You have no direct benefit by participating in this research project.
  - By participating in the research project, you support basic research.
- 40

41

42 **Risk and burden**

- 43
- The methods used are only associated with extremely low risks.
- 44

45 With your signature at the end of this document, you confirm you are participating voluntarily and  
46 that you have understood the contents of the entire document.

47



48 **Detailed information**

49

50 **1. Objectives and Selection**

51 If you decide to participate in this research project, you are a *participating person*. Volunteers aged  
52 18 or older can participate in this study. There are specific inclusion and exclusion criteria, that are  
53 queried at the time of the screening, as well as directly before starting with the measurements.

54

55 In this study we would like to test and optimise new cognitive tasks centred on the evaluation and  
56 experience of fatigue. Furthermore, we would like to understand how subjectively perceived fatigue  
57 levels are associated with the functional connectivity strength in the brain. To this end, we will perform  
58 fMRI measurements. This is a pre-study for a later study in which we will investigate in patients the  
59 subjective evaluation and experience of fatigue and its association with functional connectivity.

60

61 **2. General Information**

- 62 • The study will be conducted at the Magnetic Resonance Center at the University Hospital  
63 Zurich, Rämistrasse 100, 8091 Zurich (MRI measurement).
- 64 • Participation in the study includes filling in questionnaires and one magnetic resonance im-  
65 aging (MRI) session.
- 66 • The study lasts for two years (until approx. 01/2025). A total of 115 volunteers (100  
67 participants and 15 pilot data sets) are expected to be included in this study.
- 68 • The implementation of the study follows the corresponding regulations (laws) in Switzerland.  
69 In addition, we follow all internationally recognized guidelines. The study has been checked  
70 and approved by the Cantonal Ethics Committee.

71

72 **What is magnetic resonance imaging?**

73 Magnetic resonance (abbreviation "MR") or magnetic resonance imaging (abbreviation "MRI") is an  
74 imaging procedure. It generates images from inside the body, to help us study the structure and  
75 function of organs and tissues.

76 For the imaging procedure, the person to be examined is placed in a strong magnetic field, which is  
77 generated by a machine shaped like a tube. During the course of the investigation, the device creates  
78 additional magnetic fields that are very much weaker than the main magnetic field surrounding us.  
79 The switching of these additional fields is noticeable by the knocking and humming noises that can  
80 achieve a volume of up to 100 decibels (the noise can be reduced strongly by using ear protection).  
81 The device also uses radio waves similar to those used by radios and mobile phones. The various  
82 fields are combined to encourage the hydrogen atoms in the body to create a resonance signal. This  
83 signal is received by highly sensitive antennas, and is combined to an image by powerful computers.  
84 In contrast to x-ray examinations or investigations with a computer tomograph (CT), MRI uses no  
85 radioactive radiation.

86

87 **3. Participation Procedure**

88 Participation in the study includes an initial online screening that involves questions about the  
89 inclusion and exclusion criteria and a questionnaire measuring fatigue. If you are eligible to  
90 participate in the study, this is followed by online questionnaires that you can fill in at home and  
91 one MRI measurement at the University Hospital Zurich.

92

93 To note before the study appointment (see also point 5 "Duties"):

- 94 • If you should fall ill shortly before the study appointment (even if you do not consider to be  
95 seriously ill, e.g. a cold), we would ask you to please contact the experimenter immediately,  
96 so that we may evaluate whether participation is reasonable or possible.
- 97 • Please, do not drink alcohol within 24 hours before the study appointment.
- 98 • Please refrain from taking any pain killers or other medication within 48 hours before the  
99 study appointment.



- 100
- Should a medication intake still be necessary, please contact the investigator and tell him the name of the medicine you are taking. Together with the medical team of the Translational Neuromodeling Unit (TNU) it will then be decided whether the study date needs to be postponed or whether a study participation is unfortunately not possible.
- 101
- 102
- 103
- Please, do not consume cannabis within 14 days before the study appointment.
  - Please bring a valid ID card (e.g. identity card or student ID) to the study appointment.
- 104
- 105
- 106

107 Additional points to note before the MRI-measurement:

- For contact lens wearers: During the measurement, lenses must be removed. Therefore, please bring a contact lens case, contact lens solution, and if necessary your reading glasses with you.
  - All metallic items on the body (jewellery/ piercings) must be removed for the MRI.
  - For safety reasons, we have to ask women of childbearing age (*“Not in menopause yet and last menstruation less than 12 month ago, not surgically sterilized, ovaries and/or uterus not surgically removed”*) about a possible pregnancy. If you are unsure about this, participation can only take place if a pregnancy test is carried out and if this test is negative. Please, drink a glass of water before the measurement to be able to perform this test.
- 110
- 111
- 112
- 113
- 114
- 115
- 116

117

118 Directions to the MR-center of the USZ by tram:

119 From Zurich main train station use tram 10 (direction Oerlikon/airport) or tram 6 (direction Zoo) to  
120 the stop ETH/University Hospital. From Bellevue use tram 9 (direction Hirzenbach) also to the stop  
121 ETH/University Hospital. The University Hospital is well visible from the stop. The main entrance of  
122 the university hospital is located opposite to the main entrance of the ETH. In front of the university  
123 hospital is a golden statue. Enter the university hospital at the main entrance. Follow the aisle straight  
124 to the end where you will see three purple elevators on the right hand side, and travel 2 floors down  
125 into floor V. From the elevator the signs to the MR-center are well visible. Follow the signs for the  
126 MR-center and turn right twice until you are at the end of a slightly downward corridor, where you  
127 will find the entrance to the MR-center. With the publicly available phone you can call the internal  
128 number (59573) to indicate your arrival. The experimenter will then collect you from the reception  
129 area.

130

131 About the online pre-screening:

- You will be asked to give your consent for the screening of the inclusion and exclusion criteria. To that end, you will be asked to answer questions such that these criteria and inclusion and exclusion criteria regarding the participation in MRI-studies can be evaluated.
  - Additionally, you will be asked to fill in an online questionnaire to assess fatigue. Please note, that our study design is not suitable to make medical diagnosis.
  - Based on the results of these questionnaires we will evaluate whether a participation in this study is possible.
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139

140 About the online questionnaires:

141 You will be asked to provide your consent to participate in this part of the study. Thereof, you will be  
142 asked to fill in questionnaires on your psychological well-being, on your demographics and you will  
143 be asked to write down situations during or after which you experienced the strongest fatigue. These  
144 questionnaires will be filled in online (approx. 1 h 25 minutes).

145

146 About the 3T MRI appointment:



- 147 • The appointment takes place in the Magnetic Resonance Centre at the University Hospital  
148 Zurich, Rämistrasse 100, 8091 Zurich.
- 149 • First, we will check the inclusion and exclusion criteria, the duties and for your safety the MR-  
150 inclusion and exclusion criteria (MR safety questionnaire). Female participants will be asked  
151 whether a pregnancy might be possible. If you are unsure, a pregnancy test needs to be  
152 performed before the MR measurement and must be negative.
- 153 • Subsequently, you will be asked to fill in questionnaires regarding your sleepiness and your  
154 usual sleeping habits and to summarise the fatigue situations previously written down.
- 155 • You will receive special clothes for the MR examination. Lockers for your own clothes and  
156 changing rooms are available on site.
- 157 • It is important, that all personal items (e.g. wallet, credit cards etc.) and metallic objects (e.g.  
158 piercings, necklace, earrings, hair clips etc.) are removed from your body and are safely  
159 stored in the lockers.
- 160 • For the MR measurement you will be comfortably positioned on the scanner bed and you will  
161 be moved inside the tubular MRI scanner. The overall duration of the MR examination will be  
162 approximately 65 minutes.
- 163 • You will receive hearing protection from the experimenter.
- 164 • During the measurements, we ask you to be as relaxed and calm as possible, not to move  
165 your head, not to speak, and also not to move your facial muscles if possible. If necessary,  
166 however, you can contact the experimenter at any time via intercom. You can also stop the  
167 measurement at any time by pressing an emergency button.
- 168 • During the MRI tasks, you will be presented with questions and instructions on the screen.  
169 We will record your answers as well as your heart rate and breathing and monitor them ac-  
170 cordingly. In addition, we will monitor you via a camera. The real-time video only serves mon-  
171 itoring purposes and will not be recorded or saved.
- 172 • The total duration of this session is approx. 3 h, including a break outside the MRI scheduled  
173 after the first half of the measurement
- 174 • The financial compensation for your participation will be paid to you at the end of the study.  
175

176 We may have to exclude you from the research project prematurely. This can happen if you are  
177 unable to follow the study instructions or if you unexpectedly become unwell during the visit.  
178

#### 179 **4. Benefit**

180 You will not personally benefit from your participation. With your participation in the study, you will  
181 support basic research.  
182

#### 183 **5. Voluntariness and Obligations**

184 You are participating voluntarily. If you do not wish to participate in this research project or if you wish  
185 to withdraw your participation at a later timepoint, you do not have to give any reasons for this.  
186

187 If you are participating in this research project, it is necessary that you adhere to the specifications  
188 and requirements of the study described in the research protocol.  
189

190 These rules are necessary for your health and safety. During the study, we will support you in this as  
191 much as possible. Furthermore, you are obliged to follow the instructions of the experimenter and to  
192 adhere to the research protocol (see «To note before the study appointment», point 3 «Participation  
193 Procedure»).

#### 194 **6. Risks and Burdens**

196 According to current knowledge, MRI examinations are without health risks. There are only with  
197 regard to metal parts or electronic implants in the body known risks. In addition, the MR  
198 measurement can cause claustrophobia or discomfort due to the confined space. It is therefore



199 important that you fill in the "MR safety questionnaire" conscientiously. The staff in charge will be  
200 happy to assist you.

201

202 MRI devices have been routinely used in hospitals for diagnostic purposes for many years without  
203 any negative consequences for health. Please avoid sudden movements within the magnetic field;  
204 in rare cases this may cause slight nerve irritation and associated slight temporary dizziness or  
205 metallic taste in the mouth. Few people report brief light perceptions, so-called phosphenes. For the  
206 radio waves used in this study, the upper limits are set similar to those of mobile phones and these  
207 are strictly adhered to during MRI examinations. In this way, heating of the body is avoided. You will  
208 be given hearing protection to protect you from the tapping noise during the examination. During the  
209 measurement, the person conducting the examination is in the adjacent room. You can communicate  
210 with the experimenter at any time via the intercom system.

211

212 According to current knowledge, magnetic resonance imaging is considered a safe examination  
213 method. However, there is currently not enough data available to rule out hidden risks to the unborn  
214 child during pregnancy.

215 The reservations about the use of an MRI in early pregnancy are based on the fear that due to the  
216 static magnetic fields and the changing magnetic fields in the radiofrequency range, the fetal tissue,  
217 which is particularly sensitive in the phase of organogenesis, could be heated and thus damaged. It  
218 is also unclear what consequences the high noise level during the examination has for the unborn  
219 child. At present, it is therefore recommended to avoid MRI examinations during pregnancy.

220 For these reasons, you will unfortunately not be able to take part in the study if you are pregnant and  
221 you will be asked on the day of the MR-measurement whether pregnancy is possible. If you are  
222 unsure, a pregnancy test is mandatory before the MR-measurement.

223 The behavioural tasks do not involve any risks. During the MR-measurement, you can contact and  
224 communicate with the experimenter at any time.

225

## 226 7. Results

227 There are:

- 228 1. individual results of the research project that affect you directly,
- 229 2. individual results of the research project, which are discovered unintentionally (so-called  
230 incidental findings)

231

232 pt 1: During the course of the project the experimenter will inform you about any new results and  
233 findings that are important for you personally. You will be informed verbally and in writing and you  
234 can then decide again whether you want to continue participating in the project.

235

236 pt 2: Incidental findings are unexpected findings that are not directly related to the research project  
237 and that have been discovered by chance.

238 The methods used in this study are not suitable for clinical diagnostics. Nevertheless, it can happen  
239 that an incidental finding is detected in MR images and/or questionnaire responses. In the case of  
240 such incidental findings, or if the analysis of your data could contribute to the prevention, detection  
241 or treatment of existing or anticipated future diseases, you can choose in advance whether we  
242 should:

- 243 a) inform you of the results (and, at your request, a doctor of your choice);
- 244 b) not inform you about the results;
- 245 c) inform a person of your choice about the results (for example relatives, your doctor, etc.).

246

247 Please fill in the name and contact details, as well as your choice on the informed consent form,  
248 which can be found at the end of this document.

249



250 **8. Confidentiality of data**

251

252 **8.1 Data processing and encoding**

253 For this research project, data about your person and health will be collected and processed, partly  
254 in automated form. During data collection your data will be encrypted. Encryption means that all  
255 reference data that could identify you (name, date of birth, etc.) is deleted and replaced by a code.  
256 People who do not have access to this key list cannot draw any conclusions about you. The key list  
257 is always kept password-protected under lock and key at the Translational Neuromodeling Unit  
258 (TNU) University Zurich & ETH Zurich. Those people who do not know the key can therefore not  
259 draw any conclusions about your person.

260 In the case of a publication, the data is therefore also not traceable to you as an individual. Your  
261 name will never appear on the internet or in a publication.

262 Increasingly, there is a requirement from scientific journals and government research funding  
263 organisations that when research results are published, the individual data (so-called raw data) must  
264 be submitted, made accessible or shared. If we meet this requirements, then the data is always  
265 encrypted and therefore also not traceable to you as a person. The study personnel and the TNU  
266 database administrators who have access to your data are bound by professional secrecy. The  
267 requirements of data protection are complied with at all times and you, as a participant, have the  
268 right to inspect your data at any time.

269

270 If data is sent abroad, stored there and analysed for this project (without further use): The data is  
271 sent encrypted, examined there for this project and archived for 10 years. Only persons or institutions  
272 authorised by the TNU have access to this encryption. The institution abroad has equivalent  
273 standards to the institution in Switzerland. The authorised person/institution that ensures equivalent  
274 data protection abroad is responsible for compliance with national and international data protection  
275 guidelines.

276

277 Very few professionals will see your unencrypted data, and only to carry out tasks within the research  
278 project. These persons are subject to professional confidentiality. As a participant, you have the right  
279 to access your data. Possibly this project will be reviewed by the Cantonal Ethics Committee or by  
280 the institution that initiated the project. The project leader may need to disclose your personal and  
281 medical data for such audits/ inspections. Likewise, in exceptional cases, a representative of the  
282 insurance company may also need to look at your data. However, this inspection is limited to the  
283 data that is absolutely necessary to deal with a very unlikely claim. All persons involved must  
284 maintain absolute confidentiality.

285

286 **8.2 Data protection**

287 All data protection specifications are strictly adhered to. It is possible that your data may need to be  
288 transmitted in encrypted form, for example for publication, and may be made available to other  
289 researchers. If health-related data is stored on site, it constitutes a database for research purposes.  
290 Data will be archived in encrypted form as part of this project in a database for research purposes  
291 for at least ten years.

292

293 **8.3 Data protection in case of further use**

294 Your data could be used for answering other questions at a later date at the Translational  
295 Neuromodeling Unit, University of Zurich & ETH Zurich and/or could later be transferred to another  
296 database in Switzerland or abroad and used for as yet undefined research (further use). This other  
297 database must comply with the same standards as the database for this project.

298

299 The re-use of data is important to us because scientific journals and government research funding  
300 organisations increasingly require that when research results are published, the data must be made  
301 freely available to other researchers.

302

303 For this further use, we ask you to sign another consent form at the very end of this document. This  
304 second consent is independent of your participation in this project.



305

306 **9. Rights of access during inspections**

307 This research project may be reviewed by the Cantonal Ethics Committee. The project management  
308 must then disclose your data for such checks. All persons involved must maintain absolute  
309 confidentiality.

310

311 **10. Withdrawal**

312 You can withdraw from the research project at any time if you wish, without giving a reason. In this  
313 case, however, the data collected up to that point will still be stored and evaluated in encrypted form.  
314 Please check that you agree with this before participating in the project.

315

316 You also have the right to withdraw your consent to the further use of your data at any time without  
317 giving reasons. In the context of collaborations with external scientific partners, only encrypted, non-  
318 genetic, health-related personal data is passed on, i.e. the recipient cannot know that the data  
319 originates from you.

320

321 **11. Compensation**

322 If you have completed the screening, you can win a voucher from "WISHCARD" worth CHF 100 .-,  
323 with a draw taking place after every 100 study participants.

324

325 If you subsequently participate in this research project, you will receive compensation for this in the  
326 amount of CHF 90.-. Expenses (e.g. travel expenses) are not reimbursed.

327

328 If you withdraw from the study, you will receive compensation for the number of hours you have  
329 participated in.

330

331 There are no costs for you or your health insurance for participating.

332

333 **12. Liability**

334 In the unlikely event that you suffer damage as a result of the project, the institution responsible for  
335 carrying out the project is liable. This liability applies if it can be proven that the damage is due to the  
336 study. The Translational Neuromodeling Unit is covered by an insurance policy taken out by the  
337 Finance Department of the canton of Zurich at «Zürich-Versicherung», to cover liability in the event  
338 of damage. If you have suffered damage, please contact the project leader (see contact details).

339

340 **13. Funding**

341 The research project is supported by research funds of University Zurich and ETH Zurich for the  
342 Translational Neuromodeling Unit (Prof. K.E. Stephan).

343

344 **14. Contact person(s)**

345 You may ask questions about project participation at any time. Also, if you have any uncertainties  
346 that arise during the research project or afterwards, please contact:

347

348 Project Leader:

349 Dr. Sandra Iglesias, PhD

350 Translational Neuromodeling Unit (TNU)

351 Institute for Biomedical Engineering

352 University of Zurich and ETH Zurich

353 Wilfriedstrasse 6, 8032 Zürich

354 Phone: 044 634 91 23,

355 Email: [qfmri@ethz.ch](mailto:qfmri@ethz.ch)



356 **Informed Consent**

357

358 **Written declaration of consent to participate in a research project**

359 Please read this form carefully. Please ask if there is anything you do not understand or would like  
360 to know. Your written consent is required for participation.

361

<b>BASEC-Number (after submission):</b>	2022-02308										
<b>Title of research project (scientific and lay language):</b>	<b>Predicting individual fatigue levels based on brain connectivity – Pilot Study</b> (Acronym: QFMRI)										
<b>Responsible institution (Project management with address):</b>	Translational Neuromodeling Unit Institut für Biomedizinische Technik Universität Zürich und ETH Zürich Wilfriedstrasse 6, 8032 Zürich										
<b>Place of execution:</b>	Translational Neuromodeling Unit Institut für Biomedizinische Technik Universität Zürich und ETH Zürich Wilfriedstrasse 6, 8032 Zürich  Magnetresonanzzentrum Universitätsspital Zürich Rämistr. 100, 8091 Zürich										
<b>Project Leader of the research project at the study site</b>	Dr. Sandra Iglesias, PhD										
<b>Participating person: Name und surname (in print letters):</b>	.....										
<b>Date of birth:</b>	<table border="1" style="display: inline-table; border-collapse: collapse;"><tr><td style="width: 20px; height: 20px; text-align: center;">D</td><td style="width: 20px; height: 20px; text-align: center;">D</td><td style="width: 10px; text-align: center;">.</td><td style="width: 20px; height: 20px; text-align: center;">M</td><td style="width: 20px; height: 20px; text-align: center;">M</td><td style="width: 10px; text-align: center;">.</td><td style="width: 20px; height: 20px; text-align: center;">Y</td><td style="width: 20px; height: 20px; text-align: center;">Y</td><td style="width: 20px; height: 20px; text-align: center;">Y</td><td style="width: 20px; height: 20px; text-align: center;">Y</td></tr></table>	D	D	.	M	M	.	Y	Y	Y	Y
D	D	.	M	M	.	Y	Y	Y	Y		
<b>Gender:</b>	<input type="checkbox"/> male <input type="checkbox"/> female <input type="checkbox"/> diverse										

362

- 363 ▪ I have been informed orally and in writing by the undersigned experimenter of the trial or by the
- 364 investigator about the purpose, the procedure of the research project, about possible advantages
- 365 and disadvantages as well as about possible risks.
- 366 ▪ I am voluntarily participating in this research project and accept the content of the written study
- 367 information provided on the above research project. I have had sufficient time to make my
- 368 decision.
- 369 ▪ My questions in relation to the participation in this research project have been answered. I keep
- 370 the written study information and receive a copy of my written consent form.
- 371 ▪ I agree that the responsible experts of the project and the Ethics Committee in charge of this
- 372 research project may inspect my unencrypted data for testing and control purposes, but in strict
- 373 compliance with confidentiality.





- 374   ▪ In the case of incidental findings in the course of this study that directly affect my health:
- 375    a)  I want to be informed in any case. If you wish that we additionally inform a doctor of your
- 376        choice, please enter the name and contact details here:
- 377        .....
- 378    b)  I do not want to be informed.
- 379    c)  I would like to leave the decision to the following person (name incl. contact details):
- 380        (  above-mentioned)
- 381        .....
- 382    ▪ I know that my health-related and personal data can only be passed on in encrypted form for
- 383        research purposes for this research project (also abroad). The sponsor guarantees that data
- 384        protection in accordance with Swiss standards will be maintained.
- 385    ▪ I can withdraw from participation at any time and without giving reasons. The data collected up
- 386        to that point will still be used for analyses of the research project.
- 387    ▪ I am informed that an insurance policy covers damages resulting from the research project.
- 388    ▪ I am aware that I must comply with the obligations stated in the information document. In the
- 389        interest of my health, the experimenter or the project leader may exclude me at any time.
- 390    ▪ I confirm that all the information I provide during my participation in the study is correct.

391

Place:  ..... Date:	Signature participating person  .....								
<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <tr> <td style="width: 25px; height: 25px;">D</td> <td style="width: 25px; height: 25px;">D</td> <td style="width: 25px; height: 25px;">M</td> <td style="width: 25px; height: 25px;">M</td> <td style="width: 25px; height: 25px;">Y</td> <td style="width: 25px; height: 25px;">Y</td> <td style="width: 25px; height: 25px;">Y</td> <td style="width: 25px; height: 25px;">Y</td> </tr> </table>	D	D	M	M	Y	Y	Y	Y	
D	D	M	M	Y	Y	Y	Y		

392

393

---

394 **Confirmation of the experimenter:** I hereby confirm that I have explained the nature, significance

395 and scope of the research project to this participant. I assure that I will fulfil all obligations in

396 connection with this research project in accordance with the law applicable in Switzerland. If, in the

397 course of the research project, I learn of aspects that could influence the readiness of the

398 participating person to take part in the research project, I will inform him/her immediately.

399

400

Place:  ..... Date:	Name und surname of the experimenter (in print letters)  .....								
<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <tr> <td style="width: 25px; height: 25px;">D</td> <td style="width: 25px; height: 25px;">D</td> <td style="width: 25px; height: 25px;">M</td> <td style="width: 25px; height: 25px;">M</td> <td style="width: 25px; height: 25px;">Y</td> <td style="width: 25px; height: 25px;">Y</td> <td style="width: 25px; height: 25px;">Y</td> <td style="width: 25px; height: 25px;">Y</td> </tr> </table>	D	D	M	M	Y	Y	Y	Y	Signature of the experimenter
D	D	M	M	Y	Y	Y	Y		



401 **Informed consent for further use of data of the participating person**

<b>Name und surname (in print letters):</b>	.....										
<b>Date of birth:</b>	<table border="1"> <tr> <td>D</td><td>D</td><td>.</td><td>M</td><td>M</td><td>.</td><td>Y</td><td>Y</td><td>Y</td><td>Y</td> </tr> </table>	D	D	.	M	M	.	Y	Y	Y	Y
D	D	.	M	M	.	Y	Y	Y	Y		
<b>Gender:</b>	<input type="checkbox"/> male <input type="checkbox"/> female <input type="checkbox"/> diverse										

402  
403 I give permission that my encrypted data from this research project be further used for research. To  
404 this end, we will store the data collected in encrypted form in scientific databases - as increasingly  
405 required by scientific organisations and journals – or share the encrypted data with other researchers  
406 under data protection conditions (Data Use Agreements) so that it can be used for future research  
407 projects. This consent is valid indefinitely.

408  
409 I understand that the data is encrypted and the key is kept secure. The data can be sent to other  
410 databases for analysis at national and international level if they adhere to the same standards as in  
411 Switzerland. All legal requirements for data protection are complied with.

412  
413 I decide voluntarily and can withdraw this decision at any time. If I withdraw, my data will remain  
414 encrypted, as the data would otherwise lose its value for future research projects. I only inform the  
415 project leader and do not have to justify this decision.

416  
417 Usually, all the data is evaluated as a whole and the results are published in summary form. If there  
418 is a result that is important for my health, it is possible that I will be contacted. If I do not wish to be  
419 contacted, I will inform the project leader.

420  
421 I give my permission that my data be anonymised and I understand that in this case I can neither be  
422 informed about random results nor withdraw from the research project.

423  
424 If results from the data are commercialised, I have no claim to a share of the commercial use.  
425

<b>Place:</b>	<b>Signature participating person</b>										
.....	.....										
<b>Date:</b>											
<table border="1"> <tr> <td>D</td><td>D</td><td>.</td><td>M</td><td>M</td><td>.</td><td>Y</td><td>Y</td><td>Y</td><td>Y</td> </tr> </table>	D	D	.	M	M	.	Y	Y	Y	Y	
D	D	.	M	M	.	Y	Y	Y	Y		

426  
427

428 **Confirmation by the experimenter:** I hereby confirm that I have explained to this participant the  
429 nature, significance and scope of the further use of data.

430

<b>Place:</b>	<b>Surname and name of experimenter (in print letters)</b>										
.....	.....										
<b>Date:</b>	<b>Signature of the experimenter</b>										
<table border="1"> <tr> <td>D</td><td>D</td><td>.</td><td>M</td><td>M</td><td>.</td><td>Y</td><td>Y</td><td>Y</td><td>Y</td> </tr> </table>	D	D	.	M	M	.	Y	Y	Y	Y	
D	D	.	M	M	.	Y	Y	Y	Y		

431